Contineum Therapeutics

New Capabilities

Developing a different LPA1 receptor antagonist in Phase 2 testing

Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a Phase 3 trial, but only at the lower of two tested doses. The 60 milligram dose slowed lung function decline in patients with idiopathic pulmonary fibrosis, while the 120 milligram dose fell short of statistical significance.

Updated Oct 29